European Union - English - EMA (European Medicines Agency)

ceva santé animale - benazepril hydrochloride, spironolactone - cardiovascular system - dogs - for the treatment of congestive heart failure caused by chronic degenerative valvular disease in dogs (with diuretic support as appropriate).

United Kingdom - English - VMD (Veterinary Medicines Directorate)

ceva animal health ltd - benazepril hydrochloride, spironolactone - chewable tablet - cardio vascular - dogs

United Kingdom - English - VMD (Veterinary Medicines Directorate)

ceva animal health ltd - benazepril hydrochloride, spironolactone - chewable tablet - cardio vascular - dogs

United Kingdom - English - VMD (Veterinary Medicines Directorate)

ceva animal health ltd - benazepril hydrochloride, spironolactone - chewable tablet - cardio vascular - dogs

Canada - English - Health Canada

ceva animal health inc - benazepril hydrochloride; spironolactone - tablet (chewable) - 5mg; 40mg - benazepril hydrochloride 5mg; spironolactone 40mg - dogs

Canada - English - Health Canada

ceva animal health inc - benazepril hydrochloride; spironolactone - tablet (chewable) - 10mg; 80mg - benazepril hydrochloride 10mg; spironolactone 80mg - dogs

Canada - English - Health Canada

ceva animal health inc - benazepril hydrochloride; spironolactone - tablet (chewable) - 2.5mg; 20mg - benazepril hydrochloride 2.5mg; spironolactone 20mg - dogs

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone tablets, usp are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: spironolactone levels may be exceptiona

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone tablets, usp are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: spironolactone levels may be exceptiona

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone is indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: aldosterone levels may be exceptionally high in this condition. spi